Gastrointestinal Endoscopy

The Inner Circle Acknowledges, Howard Siegel, MD as a Pinnacle Lifetime Member

Retrieved on: 
Monday, February 19, 2024

NEW YORK, Feb. 19, 2024 /PRNewswire/ -- Prominently featured in The Inner Circle, Howard Siegel, MD is acknowledged as a Pinnacle Lifetime Member for his contributions as a Gastroenterologist with 57 Years of Dedication and Expertise.

Key Points: 
  • NEW YORK, Feb. 19, 2024 /PRNewswire/ -- Prominently featured in The Inner Circle, Howard Siegel, MD is acknowledged as a Pinnacle Lifetime Member for his contributions as a Gastroenterologist with 57 Years of Dedication and Expertise.
  • His unwavering commitment to patient care has made him a respected figure in the field of gastroenterology.
  • Dr. Siegel's practice, Manhattan Internal Medicine Associates, P.C., is renowned for providing advanced and personalized gastroenterological care.
  • In memory of his esteemed mentors, Dr. Siegel pays tribute to the invaluable guidance and support received from Dr. Edward King, MD, and Dr. David.

Mirai Medical Welcomes Former Boston Scientific Executive, David A. Pierce, as Non-Executive Director

Retrieved on: 
Tuesday, January 23, 2024

Mirai Medical, a cutting-edge medical technology start-up and leader in Pulsed Field Ablation (PFA) within the Gastrointestinal Tract, proudly welcomes David A.

Key Points: 
  • Mirai Medical, a cutting-edge medical technology start-up and leader in Pulsed Field Ablation (PFA) within the Gastrointestinal Tract, proudly welcomes David A.
  • Pierce's distinguished career at Boston Scientific, spanning 31 years, has been marked by numerous accomplishments and a deep understanding of the MedTech landscape.
  • His extensive experience at Boston Scientific, coupled with his deep knowledge of the industry, will undoubtedly play a pivotal role in guiding Mirai Medical's strategic direction,” said Mirai Medical CEO, Dr. Declan Soden, PhD.
  • Pierce shared his enthusiasm for joining Mirai Medical, saying, “I am honoured to be part of Mirai Medical, a company at the forefront of innovation in interventional endoscopy.

The Inner Circle Acknowledges, Abdelhai Abdelqader as a Top Pinnacle Professional

Retrieved on: 
Monday, January 22, 2024

SARASOTA, Fla., Jan. 22, 2024 /PRNewswire/ -- Prominently featured in The Inner Circle, Abdelhai Abdelqader is acknowledged as a Top Pinnacle Professional for his contributions to the field of Gastroenterology.

Key Points: 
  • SARASOTA, Fla., Jan. 22, 2024 /PRNewswire/ -- Prominently featured in The Inner Circle, Abdelhai Abdelqader is acknowledged as a Top Pinnacle Professional for his contributions to the field of Gastroenterology.
  • Dr. Abdelqader pursued higher education at Loyola University where he earned a Bachelor of Science degree.
  • Dr. Abdelqader is considered an expert in colorectal and esophageal cancer screening, as well as advanced endoscopy and surgical endoscopy.
  • Dr. Abdelhai Abdelqader is a practicing gastroenterologist based in Sarasota, FL.

Top Gastroenterology and Liver Disease Specialist, Dr. David P. Yamini, Receives Castle Connolly's 2023 Top Doctor® Award

Retrieved on: 
Thursday, November 9, 2023

BEVERLY HILLS, Calif., Nov. 9, 2023 /PRNewswire-PRWeb/ -- Dr. David Yamini has been selected as a 2023 Top Doctor® by Castle Connolly. Dr. Yamini is an accomplished physician who is double board-certified in gastroenterology and internal medicine. He serves patients in Santa Monica and Beverly Hills, CA, treating diseases and disorders of the digestive system. Dr. Yamini's medical education, training, hospital appointments and disciplinary history were rigorously screened by the Castle Connolly physician-led research team. Castle Connolly publishes its list of Top Doctors at http://www.castleconnolly.com and in a wide variety of partner publications, magazines and affiliate websites. Around 7% of the nation's top board-certified, licensed physicians have been selected as Castle Connolly Top Doctors in their regions for their specialties. Individuals do not and cannot pay to be selected as a Castle Connolly Top Doctor. Dr. David Yamini offers advanced diagnostic and therapeutic procedures and has established a reputation as one of the best Los Angeles gastroenterologists and liver disease specialists. Dr. Yamini offers expertise in issues involving the digestive tract, biliary system, liver and pancreas, with a proficiency in endoscopic retrograde cholangiopancreatography (ERCP). He takes a comprehensive approach to diagnosing and treating patients with all types of gastrointestinal (GI) problems and disorders that affect the small and large intestine, stomach, esophagus, gallbladder, liver and pancreas, including inflammatory bowel disease (Crohn's, ulcerative colitis), indigestion (dyspepsia), small intestinal bacterial overgrowth (SIBO) and irritable bowel syndrome (IBS). Dr. Yamini provides his patients with a superior level of compassionate and attentive personalized care.

Key Points: 
  • BEVERLY HILLS, Calif., Nov. 9, 2023 /PRNewswire-PRWeb/ -- Dr. David Yamini has been selected as a 2023 Top Doctor® by Castle Connolly.
  • Dr. Yamini's medical education, training, hospital appointments and disciplinary history were rigorously screened by the Castle Connolly physician-led research team.
  • Dr. David Yamini offers advanced diagnostic and therapeutic procedures and has established a reputation as one of the best Los Angeles gastroenterologists and liver disease specialists .
  • "It is such an honor to be recognized by my peers for this award," says Dr. David Yamini.

The Inner Circle Acknowledges, David Chua, M.D., FASGE as a Distinguished Healthcare Professional for his contributions to the Medical Field

Retrieved on: 
Monday, October 30, 2023

OAKBROOK, Ill., Oct. 30, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, David Chua, M.D., FASGE is acknowledged as a Distinguished Healthcare Professional for his contributions to the Medical Field.

Key Points: 
  • OAKBROOK, Ill., Oct. 30, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, David Chua, M.D., FASGE is acknowledged as a Distinguished Healthcare Professional for his contributions to the Medical Field.
  • Dr. Chua pursued a Medical Degree from the University of Santo Tomas Faculty of Medicine and Surgery.
  • He is considered an expert in colonoscopy, liver, hepatitis, Crohns, and IBS and Therapeutic Endoscopy.
  • Board certified by the American Board of Internal Medicine-Internal Medicine, and Gastroenterology by the American Board of Internal Medicine- Internal Medicine and Gastroenterology.

New Publication Highlights the Ability of the TissueCypher® Barrett’s Esophagus Test to Improve and Standardize the Clinical Management of Low-Grade Dysplasia in Patients with Barrett’s Esophagus

Retrieved on: 
Monday, August 7, 2023

The full study is available here .

Key Points: 
  • The full study is available here .
  • The study results showed the following:
    Using TissueCypher test results to guide patient management decisions, in conjunction with the standard of care (SOC), significantly increased the likelihood of patients receiving appropriate management per their known outcome.
  • Overall, the study results suggest that TissueCypher may be used to standardize the management of BE patients with NDBE, IND and LGD.
  • Use of the TissueCypher test may also improve health outcomes by identifying patients at a low risk of progression who can avoid unnecessary therapy and be managed using surveillance alone.

New study shows that WATS3D increases diagnostic yield of dysplasia in Barrett's esophagus, regardless of segment length

Retrieved on: 
Wednesday, August 2, 2023

Regardless of segment length, WATS3D is highly effective at increasing the diagnostic yield of intestinal metaplasia and dysplasia.

Key Points: 
  • Regardless of segment length, WATS3D is highly effective at increasing the diagnostic yield of intestinal metaplasia and dysplasia.
  • "WATS3D has previously shown diagnostic effectiveness for patients with known or suspected BE," said the lead author of the study, Dr. Arvind Trindade, Regional Director of Endoscopy, Northwell Health.
  • "This new study focuses on WATS3D performance in short versus long segment esophageal columnar-lined mucosa."
  • The adjunctive and absolute yields of WATS3D were calculated according to the length of the patient's BE segment.

Non-Surgical Weight Loss Procedure Offers Highly Effective and Sustainable Weight Loss in Patients With BMI of 40+

Retrieved on: 
Tuesday, July 11, 2023

This study led by True You Weight Loss evaluated the data of over 400 patients who underwent ESG between May of 2018 and March of 2022.

Key Points: 
  • This study led by True You Weight Loss evaluated the data of over 400 patients who underwent ESG between May of 2018 and March of 2022.
  • Participants’ average weight loss was 20.9% (of total body weight) at 12 months, 20.5% at 24 months, and 20.3% at 36 months.
  • 96.7% of patients lost at least 10% of their body weight – a key metabolic threshold; More than half (55.6%) lost greater than 20% of their body weight.
  • Every medical procedure, even those that are minimally invasive, has some degree of risk – particularly in patients with higher BMI.

Palatin Presents PL8177 Ulcerative Colitis Data at Digestive Disease Week Annual Conference

Retrieved on: 
Tuesday, May 9, 2023

CRANBURY, N.J., May 9, 2023 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced the presentation of the poster "Efficacy of the Melanocortin Receptor Agonist PL8177 as a Potential Therapy for Gastrointestinal Inflammatory Diseases" at the Digestive Disease Week annual meeting May 6-9, 2023 in Chicago, Illinois. The poster was presented by John Dodd, Ph.D., Senior Vice President of Preclinical Research at Palatin. The poster can be found on Palatin's website www.palatin.com.

Key Points: 
  • In preclinical studies in rat models of ulcerative colitis, oral PL8177 was found to be efficacious in reducing colonic damage and inflammation.
  • Clinical data presented in the poster shows that oral PL8177 was released in the GI tract and did not reach systemic circulation.
  • "We are looking forward to the data from an ongoing phase 2 study and the potential of PL8177 as a novel treatment for inflammatory bowel disease."
  • Digestive Disease Week® (DDW) is the largest international gathering of physicians, researchers and academics in the fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgery.

CinRx Portfolio Company CinDome Pharma Presents Encouraging Data on Deudomperidone (CIN-102) at 2023 Digestive Disease Week® Conference

Retrieved on: 
Monday, May 8, 2023

CinDome Pharma, a CinRx portfolio company, presented a poster at the 2023 Digestive Disease Week (DDW) Conference titled “Effect of Therapeutic and Supratherapeutic Doses of Deudomperidone (CIN-102) on Cardiac Repolarization in a Thorough QT (TQT) Study in Healthy Subjects.” The poster highlighted data evaluating deudomperidone, a modified formulation of domperidone, for the long-term treatment of gastroparesis.

Key Points: 
  • CinDome Pharma, a CinRx portfolio company, presented a poster at the 2023 Digestive Disease Week (DDW) Conference titled “Effect of Therapeutic and Supratherapeutic Doses of Deudomperidone (CIN-102) on Cardiac Repolarization in a Thorough QT (TQT) Study in Healthy Subjects.” The poster highlighted data evaluating deudomperidone, a modified formulation of domperidone, for the long-term treatment of gastroparesis.
  • The study presented at DDW assessed the effect of deudomperidone on electrocardiogram (ECG) parameters, including concentration-QTc (C-QTc) analysis.
  • The data demonstrated the potential of deudomperidone to decrease the risk of QT prolongation associated with the traditional formulation of domperidone.
  • Deudomperidone is being developed by CinDome as the first line therapy for chronic gastroparesis, which impacts an estimated 16 million people in the U.S.